Skip to content

Clinical trials

Pneumonia, Pneumocystis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pneumonia, Pneumocystis Clear all

107 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20041
20061
20071
20081
20091
20101
20121
20131
20141
20154
20162
20174
20182
20193
20206
20212
20236
20243
20256
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed73
Unknown status14
Recruiting8
Not yet recruiting5
Terminated3
Withdrawn2
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)36
Fisons5
U.S. Bioscience5
Glaxo Wellcome4
Assistance Publique - Hôpitaux de Paris2
Central Hospital, Nancy, France2
Jacobus Pharmaceutical2
LyphoMed2
McGill University Health Centre/Research Institute of the McGill University Health Centre2
Mundipharma Research Limited2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pneumonia, Pneumocystis107
HIV Infections59
Acquired Immunodeficiency Syndrome55
AIDS-Related Opportunistic Infections30
AIDS-Related Complex16
Pneumonia10
Pneumocystis Infections8
Respiratory Aspiration7
Infections5
Mycoses4

Trials

Showing 26 to 50 of 107. Each trial links to its page on Pharma Observatory.

7 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.